支气管动脉灌注化疗联合华蟾素胶囊治疗晚期非小细胞肺癌的临床观察

摘要

OBJECTIVE:To observe clinical efficacy and toxic reaction of bronchial artery infusion(BAI)chemotherapy com-bined with Cinobufacini capsule in the treatment of advanced non-small cell lung cancer(NSCLC). METHODS:A total of 126 cas-es of advanced NSCLC diagnosed in stage Ⅲb-Ⅳ were randomly divided into observation and control group,63 cases in each group. Both of them were treated by BAI with taxotere/cisplatin(TP regimen),once every three weeks for a cycle,a total of 5 cy-cles;observation group was additionally given Cinobufacini capsule 500 mg/time,three times a day,on the basis of BAI chemo-therapy,for 15 weeks. Clinical efficacy,KPS,survival rate and toxic reaction of 2 groups were observed. RESULTS:The total ef-fective rate(82.54%)of observation group was better than that(63.49%)of control group,with statistical significance(P<0.05). KPS score of observation group was significantly better than that of control group,with statistical significance (P<0.05). 1-year survival rate of observation group and control group were 65.08% and 30.15%,2-year survival rate of them were 19.05% and 4.76%,with statistical significance(P<0.05). Adverse reactions of two groups was mainly marrow suppression and gastrointesti-nal reaction,marrow suppression degree and the incidence of nausea and vomiting in observation group was lighter than control group,with statistical significance (P<0.05). CONCLUSIONS:BAI combined with Cinobufacini capsule in the treatment of ad-vanced NSCLC can improve short-term curative effect and long-term survival rate,and can improve the survival quality with little toxic effect.%目的：观察支气管动脉灌注（BAI）化疗联合华蟾素胶囊治疗晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法：选取符合条件的Ⅲb-Ⅳ期NSCLC患者126例，按随机数字表法分为观察组和对照组，各63例。两组患者均用多西他赛+顺铂（TP）方案行BAI化疗，3周为1个疗程，共5个疗程；观察组患者在BAI化疗基础上加服华蟾素胶囊，500 mg/次，3次/d，共15周。观察两组患者临床疗效、Kamofsky评分、生存率、毒副反应。结果：观察组近期总有效率（82.54％）优于对照组（63.49％），差异有统计学意义（P＜0.05）；观察组Kamofsky评分明显优于对照组，差异有统计学意义（P＜0.05）；观察组和对照组患者1、2年生存率分别为65.08％、19.05％和30.15％、4.76％，差异有统计学意义（P＜0.05）；两组患者毒副反应主要为骨髓抑制和胃肠道反应，观察组患者骨髓抑制程度及恶心、呕吐发生率较对照组减轻，差异有统计学意义（P＜0.05）。结论：BAI化疗联合华蟾素胶囊治疗晚期NSCLC能提高患者近期疗效和远期生存率，并能改善患者生存质量，且毒副反应较轻。